http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2717367-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d584042a524740a406723fe1631e49e5 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61B5-107 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-92 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-66 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61B5-107 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
| filingDate | 2019-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e16a1fb3d6cf1cecf8f023f8fa52c190 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_268f4965586a68fc9066d9b99da7fb7f http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7c093e0cffcbd4816b6595acb15031c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a4a8c4ae4539018915fe7d02216454f1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_60ff8a9cf7bf7e5faf794183960bb0d6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_fb1897b33aa56cef649dc5c92a20599d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_17ee5670f9f43b2e2caa3d60e9eabb98 |
| publicationDate | 2020-03-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2717367-C1 |
| titleOfInvention | Diagnostic technique for metabolic syndrome in schizophrenic patients receiving neuroleptic therapy |
| abstract | FIELD: medicine.SUBSTANCE: invention relates to medicine, namely to psychiatry. Presence of abdominal obesity - waist circumference (WC) more than 80 cm in females and more than 94 cm in males, blood pressure (BP) 130/85 mm Hg and more, concentration of triglycerides (TG) more than 1.7 mmol/l, concentration of high-density lipoprotein cholesterol (HDL-C) less than 1.03 mmol/l in males and less than 1.29 mmol/l in females, glucose concentration in blood plasma of 5.6 mmol/l and more. Additionally, concentrations of apolipoprotein C2 (AroC2) and apolipoprotein C3 (AroC3) are determined. If AroC2 concentration is more than 25 mcg/dl and AroC3 is more than 45 mcg / dl, metabolic syndrome is diagnosed. Method provides higher diagnostic accuracy of metabolic syndrome in patients with schizophrenia receiving neuroleptic therapy by determining WC, BP, TG, HDL-C and glucose in patients with schizophrenia and additional determination of AroC2 and AroC3 in the patients upon admission to the clinic.EFFECT: invention can be used for diagnosing metabolic syndrome in schizophrenic patients receiving neuroleptic therapy.1 cl, 1 tbl, 1 ex |
| priorityDate | 2019-03-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 94.